New Findings Show COVID-19 Can Persist in Cancer Patients and Impact Treatments
Research reveals that COVID-19 can persist in the gastrointestinal tissues of cancer patients long after infection, potentially affecting treatment outcomes and inflammation levels. Learn more about these groundbreaking findings from the University of Minnesota.
Recent research conducted by the University of Minnesota Medical School has shed light on how COVID-19 can remain in the bodies of cancer patients long after initial infection, potentially influencing treatment outcomes. The study, published in iScience, focused on the persistent presence of the virus in gastrointestinal tissues of immunocompromised cancer patients, particularly those who had undergone transplant therapies. Researchers found that even six weeks after a positive nasal swab test, traces of the virus could still be detected in the gut lining. This lingering virus was associated with increased inflammation and tissue damage. Notably, a specific inflammatory marker, SERPINA1, was identified as being consistently linked to tissue inflammation in these cases.
The findings suggest that COVID-19’s persistence in the gastrointestinal tract might contribute to poorer outcomes during cancer treatment, especially in patients with elevated levels of inflammatory markers. Experts like Dr. Justin Hwang emphasized the potential importance of measuring GI tissue markers such as SERPINA1 before clinical decisions, particularly when considering transplantation therapies.
Furthermore, Dr. Emil Lou highlighted the significance of understanding if this persistent viral presence has longer-term effects, such as connections to Long COVID or other complications in this vulnerable population. The study underscores the need for further research involving larger cohorts to better understand the implications of persistent COVID-19 infection and the role of inflammation in cancer patients. Close monitoring may be necessary for patients with high SERPINA1 levels to mitigate increased inflammation risks associated with cancer treatments.
This study provides critical insights into the ongoing challenges posed by COVID-19 in immunocompromised patients, emphasizing the importance of tailored treatment strategies and further investigation into the virus’s long-term effects.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Assessing Risk Factors in Children with Congenital Heart Defects
A pivotal study identifies critical risk factors impacting survival in children with congenital heart defects awaiting or undergoing heart transplantation, guiding early intervention strategies.
Rising Incidence of Skin Cancer Among Older Men as Global Population Ages
Skin cancer rates among older men are rising globally, driven by demographic shifts and increased ultraviolet exposure. Learn about recent research on this growing health concern and the importance of early detection and prevention.
Probiotic Treatment Reduces Antibiotic-Resistant Bacteria in Preterm Infants' Gut, New Research Finds
A new study demonstrates that probiotic supplementation in preterm infants reduces antibiotic-resistant bacteria and supports healthy gut microbiome development, offering promising benefits against infections and antimicrobial resistance.
Urgent Need for Regulatory Action on Vape Device Design to Prevent Young Māori Vaping
Research highlights how discreet vape device designs promote normalization and uptake among young Māori, urging urgent regulatory action to curb youth vaping.